Promacta (Eltrombopag Powder for Suspension) and Talazoparib Tosylate
Determining the interaction of Promacta (Eltrombopag Powder for Suspension) and Talazoparib Tosylate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of this efflux membrane transporter. However, the effect of BCRP inhibitors on the pharmacokinetics of talazoparib has not been studied in vivo. MANAGEMENT: Caution is recommended when talazoparib is coadministered with inhibitors of BCRP. Some authorities advise that concomitant use of talazoparib with potent BCRP inhibitors such as cyclosporine should be avoided (UK). Patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling. References "Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group, New York, NY. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Coadministration with inhibitors of breast cancer resistance protein (BCRP) may increase the plasma concentrations of talazoparib, which has been shown in vitro to be a substrate of this efflux membrane transporter. However, the effect of BCRP inhibitors on the pharmacokinetics of talazoparib has not been studied in vivo.
MANAGEMENT: Caution is recommended when talazoparib is coadministered with inhibitors of BCRP. Some authorities advise that concomitant use of talazoparib with potent BCRP inhibitors such as cyclosporine should be avoided (UK). Patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.
- "Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: eltrombopag
Brand name: Promacta
Synonyms: Promacta
Generic Name: talazoparib
Brand name: Talzenna
Synonyms: Talazoparib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Promacta (Eltrombopag Powder for Suspension)-Talimogene laherparepvec
- Promacta (Eltrombopag Powder for Suspension)-Talimogene laherparepvec Injection
- Promacta (Eltrombopag Powder for Suspension)-Taliva
- Promacta (Eltrombopag Powder for Suspension)-Taltz
- Promacta (Eltrombopag Powder for Suspension)-Taltz (Ixekizumab Auto-Injectors)
- Promacta (Eltrombopag Powder for Suspension)-Taltz (Ixekizumab Prefilled Syringes)
- Talazoparib Tosylate-Promacta (Eltrombopag Tablets)
- Talazoparib Tosylate-Promethazine
- Talazoparib Tosylate-Promethazine and Phenylephrine
- Talazoparib Tosylate-Promethazine Hydrochloride
- Talazoparib Tosylate-Promethazine injection
- Talazoparib Tosylate-Promethazine Injection, Intravenous